Tempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%

Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) fell 6.8% during trading on Friday . The company traded as low as $3.58 and last traded at $3.59. 462,763 shares were traded during mid-day trading, a decline of 54% from the average session volume of 1,007,446 shares. The stock had previously closed at $3.85.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TPST. Jefferies Financial Group began coverage on Tempest Therapeutics in a research report on Thursday, February 8th. They issued a "buy" rating and a $15.00 price target on the stock. William Blair restated an "outperform" rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Scotiabank began coverage on Tempest Therapeutics in a research report on Thursday, March 14th. They issued a "sector outperform" rating and a $13.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $47.00 price target on shares of Tempest Therapeutics in a research report on Wednesday, March 20th.

Tempest Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 4.29 and a quick ratio of 4.29. The stock has a 50-day simple moving average of $3.87 and a 200-day simple moving average of $3.69. The stock has a market cap of $79.66 million, a P/E ratio of -1.88 and a beta of -1.76.

Tempest Therapeutics (NASDAQ:TPST - Get Free Report) last released its earnings results on Tuesday, March 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. Research analysts forecast that Tempest Therapeutics, Inc. will post -1.58 earnings per share for the current year.

Institutional Trading of Tempest Therapeutics

A number of hedge funds have recently made changes to their positions in the company. MayTech Global Investments LLC acquired a new stake in shares of Tempest Therapeutics during the fourth quarter valued at about $44,000. Susquehanna International Group LLP acquired a new stake in shares of Tempest Therapeutics during the first quarter valued at about $26,000. Millennium Management LLC acquired a new stake in shares of Tempest Therapeutics during the second quarter valued at about $29,000. Northern Trust Corp boosted its stake in shares of Tempest Therapeutics by 147.9% during the fourth quarter. Northern Trust Corp now owns 33,598 shares of the company's stock valued at $148,000 after purchasing an additional 20,045 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Tempest Therapeutics by 52.9% during the second quarter. Geode Capital Management LLC now owns 102,244 shares of the company's stock valued at $130,000 after purchasing an additional 35,372 shares in the last quarter. 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.